Why the study?
Does the antifactor Xa activity of heparin fractions correlate with their anticoagulant efficacy in thromboplastin-activated plasma?
Does the antifactor Xa activity of heparin fractions correlate with their anticoagulant efficacy in thromboplastin-activated plasma?
The anticoagulant efficacy of heparin and LMWH in plasma is primarily driven by their antithrombin activity rather than their antifactor Xa activity.
Answers are grounded in this paper and cite their sources.
Antithrombin activity may outweigh anti-Xa for heparin's effect; animal data leaves clinical relevance open.
The antifactor Xa activities of heparin fractions are widely used as an ex vivo index of their antithrombotic efficacy. Its clinical meaning, however, remains speculative. In the study reported, we measured the effects of standard heparin, a synthetic pentasaccharide heparin (antifactor Xa activity only), and a low molecular weight heparin (LMWH) on factor Xa, factor Va, and thrombin generation in thromboplastin-activated plasma. We clearly demonstrated that the antifactor Xa activity of heparin contributed little in its anticoagulant activity. The inhibition of factor Va generation, dependent on the heparin antithrombin activity only, is of prime importance to the inhibition of thrombin generation in plasma. The inhibition of thrombin generation by the LMWH was comparable with that of standard heparin on the basis of their respective antithrombin specific activities, but not on the basis of their antifactor Xa activities.
No takes yet. Share an insight, caveat, or question.
Pieters et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: